Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01149577|
Recruitment Status : Completed
First Posted : June 23, 2010
Last Update Posted : June 23, 2010
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Sleep||Drug: Olanzapine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||April 2009|
Experimental: Schizophrenia patients
The study population of 25 schizophrenia patients constituted the active arm of the study.
06 weeks treatment with Olanzapine in a flexible dosage schedule.
- Sleep EEG [ Time Frame: 06 weeks ]Changes in Sleep EEG parameters like Total sleep time, total sleep period, sleep efficiency, sleep latency, stage shifts, stage 1 shifts, stage 1 parameters, stage 2 parameters, stage 3 parameters, stage 4 parameters, rapid eye movement (REM) parameters.
- Psychopathology [ Time Frame: 06 weeks ]Changes in psychopathological scores as measured by Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01149577
|Central Institute of Psychiatry|
|Ranchi, Jharkhand, India, 834006|
|Principal Investigator:||Mohammad Zia Ul Haq Katshu, DPM||Central Institute of Psychiatry|